Coming Soon
Learn about Acinetobacter baumannii infection diagnosis, including clinical documentation and medical coding for healthcare professionals. Find information on MDR Acinetobacter infection and Acinetobacter sepsis, covering symptoms, treatment, and prevention. This resource supports accurate medical coding and improved patient care for Acinetobacter baumannii infections.
Also known as
Acinetobacter infections
Infection caused by the Acinetobacter bacteria.
Other bacterial infections of unspecified site
Bacterial infection where the specific location is unknown.
Sepsis of unspecified origin
Systemic inflammatory response to infection, origin unknown.
Other specified bacterial agents as the cause of diseases classified elsewhere
Diseases caused by other specified bacterial agents.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the infection site documented?
When to use each related code
| Description |
|---|
| Infection caused by Acinetobacter baumannii bacteria. |
| Multi-drug resistant Acinetobacter baumannii infection. |
| Bloodstream infection caused by Acinetobacter baumannii. |
Coding sepsis solely based on "Acinetobacter" presence without documented organ dysfunction can lead to inaccurate DRG assignment and overcoding.
Documenting and coding multi-drug resistance (MDR) requires specific antibiotic susceptibility results. Lack of clarity may cause undercoding and lost revenue.
Missing documentation of the infection site (e.g., pneumonia, UTI) for Acinetobacter can hinder accurate code assignment and impact quality metrics.
Q: What are the most effective empiric antibiotic treatment options for suspected multi-drug resistant Acinetobacter baumannii infection in critically ill patients?
A: Empiric antibiotic treatment for suspected MDR Acinetobacter baumannii infection in critically ill patients is complex due to widespread resistance. Current guidelines recommend combination therapy based on local antibiograms and resistance patterns. Commonly used options include a carbapenem (if not significantly resistant), sulbactam (often combined with ampicillin), or colistin (polymyxin E) often in combination with another agent like minocycline or tigecycline. For extremely drug-resistant strains, newer agents like cefiderocol or eravacycline may be considered where available. Rapid diagnostics, including PCR and susceptibility testing, are crucial for tailoring therapy and optimizing patient outcomes. Explore how antimicrobial stewardship programs can optimize antibiotic selection and minimize the development of further resistance. Learn more about the latest resistance trends in your region by consulting local surveillance data.
Q: How can clinicians differentiate Acinetobacter baumannii sepsis from other causes of sepsis in ventilated patients based on clinical presentation and diagnostic tests?
A: Differentiating Acinetobacter baumannii sepsis from other causes of sepsis in ventilated patients can be challenging due to overlapping symptoms. Clinical clues may include risk factors such as prolonged hospitalization, prior antibiotic exposure, invasive procedures, and presence of indwelling devices. Acinetobacter infections are frequently associated with ventilator-associated pneumonia (VAP). While clinical presentation alone is insufficient, purulent sputum, worsening oxygenation, and new or persistent fever may raise suspicion. Definitive diagnosis requires laboratory confirmation. Blood cultures, though not always positive in Acinetobacter sepsis, should be obtained. Respiratory samples, such as bronchoalveolar lavage (BAL) or endotracheal aspirates, should be sent for Gram stain and culture. Consider implementing rapid diagnostic tests like PCR for quicker identification. Learn more about the role of biomarkers like procalcitonin in diagnosing and managing sepsis.
Patient presents with signs and symptoms suggestive of Acinetobacter baumannii infection, including [specify presenting symptoms, e.g., fever, chills, hypotension, tachypnea, purulent sputum, altered mental status]. Differential diagnosis includes pneumonia, sepsis, urinary tract infection, wound infection, and other nosocomial infections. The patient's medical history includes [list relevant medical history, e.g., recent hospitalization, intubation, indwelling catheters, antibiotic use, immunocompromised status]. Physical examination reveals [document relevant findings, e.g., fever of [temperature], tachycardia, respiratory distress, localized signs of infection]. Laboratory studies were ordered, including complete blood count with differential, blood cultures, urinalysis, and culture of the suspected infection site. Preliminary findings indicate [mention preliminary lab results, e.g., leukocytosis, elevated procalcitonin, positive gram-negative bacilli on Gram stain]. Based on the clinical presentation and preliminary laboratory data, the presumptive diagnosis is Acinetobacter baumannii infection. Given the potential for multi-drug resistance (MDR Acinetobacter), empiric antibiotic therapy was initiated with [specify antibiotic regimen, e.g., carbapenem, colistin, aminoglycoside] pending culture and sensitivity results. The patient will be closely monitored for response to treatment and development of complications, such as septic shock or organ dysfunction. Infection control precautions have been implemented to prevent further spread. Further diagnostic testing, including imaging studies, may be warranted depending on the patient's clinical course. ICD-10 code [appropriate code, e.g., A49.1, J15.0, B96.2 depending on the site of infection] is considered. Treatment plan includes continued monitoring, supportive care, and adjustment of antibiotic therapy based on culture and sensitivity results. The patient's prognosis will be reassessed based on response to therapy and potential complications.